Home › Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
 

Keywords :   


Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy

2015-09-16 16:16:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: on type similar controlled

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Mooncat Introduces New Hue, Holds Bi-Annual Sale
15.05European Wax Center\'s EWC Treat Brightening Ingrown Hair Wipes Awarded
15.05PBE Makes Investment in Plus-Size Adult Incontinence Products
15.05Flint Group retains EcoVadis Silver Medal for 2024
15.05Mark Andy hosts student workshop in Poland
15.05Kenvue Launches Aveeno Baby Healthy Start Wash and Balm
15.05Royal Mail owner poised to accept 3.5bn takeover bid
15.05Gold Bond Named Official Body Skin Sponsor of Sports Illustrated Swimsuit\'s 60th Anniversary Issue
More »